NK-1 receptor antagonists as antitumor drugs: A survey of the literature from 2000 to 2011

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 7, 2012, Pages 735-746

  Muñoz, Miguel ^a   Martinez Armesto, Juan ^b   Coveñas, Rafael ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b CSIC   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Antitumor; Cancer; Drug; Metastasis; Neoangiogenesis; NK 1 receptor; NK 1 receptor antagonists; Substance P

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; ANTINEOPLASTIC AGENT; APREPITANT; BEFETUPITANT; CASOPITANT; EZLOPITANT; FOSAPREPITANT; L 743310; MEN 11149; MEN 11467; N ACETYL L TRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYLESTER; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NOLPITANTIUM; PLACEBO; R 673; SPANTIDE; SUBSTANCE P; TAC 637; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESTIPITANT; VINBLASTINE; VOFOPITANT;

ADENOCARCINOMA; ANALGESIC ACTIVITY; ANTIANGIOGENIC ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; APOPTOSIS; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CHEMICAL STRUCTURE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HEADACHE; HEPATITIS; HUMAN; HYPERALGESIA; LIVER INJURY; LIVER PROTECTION; MEDICAL LITERATURE; MIGRAINE; MOOD DISORDER; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NEUROPROTECTION; NONHUMAN; POSTOPERATIVE NAUSEA AND VOMITING; PRURITUS; REVIEW; SKIN PERMEABILITY; TRANQUILIZING ACTIVITY; TUMOR CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PATENTS AS TOPIC; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 84862866571     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.697153     Document Type: Review

References (77)

1. Morgan G, Ward R, Barton M. the contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol 2004;16:549-60
2. Munoz M, Rosso M, Covenas R. A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 2010;17:504-16
3. Munoz M, Rosso M, Covenas R. the NK-1 receptor: A new target in cancer therapy. Curr Drug Targets 2011;12:909-21
4. Munoz M, Covenas R. NK-1 receptor antagonists: A new paradigm in pharmacological therapy. Curr Med Chem 2011;18:1820-31
5. Ziche M, Morbidelli L, Pacini M, et al. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 1990;40:264-78
6. Lang K, Drell TL, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004;112:231-8
7. Palma C, Bigioni M, Irrissuto C, et al. Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 2000;82:480-7
8. Bigioni M, Benzo A, Irrissuto C, et al. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 2005;16:1083-9
9. Singh D, Joshi DD, Hameed M, et al. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: Implications for bone marrow metastasis. Proc Natl Acad Sci USA 2000;97:388-93
10. Munoz M, Rosso M, Covenas R, et al. Neurokinin-1 receptors located in human retinoblastoma cell lines: Antitumor action of its antagonist, L-732,138. Invest Ophthalmol Vis Sci 2007;48:2775-81
11. Gonzalez-Moles MA, Mosqueda-Taylor A, Esteban F, et al. Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours. Oral Oncol 2008;44:1127-33
12. Brener S, Gonzalez-Moles MA, Tostes D, et al. A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. Anticancer Res 2009;29:2323-9
13. Esteban F, Gonzalez-Moles MA, Castro D, et al. Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 2009;54:258-60
14. Khare VK, Albino AP, Reed JA. the neuropeptide/mast cell secretagogue substance P is expressed in cutaneus melanocytic lesions. J Cutan Pathol 1998;25:2-10
15. Tarkkanen A, Tervo T, Tervo K, et al. Substance P immunoreactivity in normal human retina and in retinoblastoma. Ophthalmic Res 1983;15:300-6
16. Hennig IM, Laissue JA, Horisberger U, et al. Substance-P receptors in human primary neoplasms: Tumoral and vascular localization. Int J Cancer 1995;61:786-92
17. Feng F, Yang J, Tong L, et al. Substance P-immunoreactive nerve fibers are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells. Cell Biol Int 2011;35:623-9
18. Patel HJ, Ramkissoon SH, Patel PS, et al. Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc Natl Acad Sci USA 2005;102:17436-41
19. Moharita A, Harrison JS, Rameshwar P. Neurokinin receptors and subtypes as potential targets in breast cancer: Relevance to bone marrow metastasis. Drug Res Rev 2004;1:1-6
20. Peng SL. Transcription factors in the pathogenesis of autoimmunity. Clin Immunol 2004;110:112-23
21. Ramkissoon SH, Patel PS, Taborga M, et al. Nuclear factor-kappaB is central to the expression of truncated neurokinin-1 receptor in breast cancer: Implication for breast cancer cell quiescence within bone marrow stroma. Cancer Res 2007;67:1653-9
22. Munoz M, Rosso M, Robles-Frias MJ, et al. the NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 2010;90:1259-69
23. Rosso M, Robles-Frias MJ, Covenas R, et al. the NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol 2008;29:245-54
24. Munoz M, Rosso M, Perez A, et al. Antitumoural action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2005;46:2567-70
25. Munoz M, Covenas R. Neurokinin-1 receptor: A new promising target in the treatment of cancer. Discov Med 2010;10:305-13
26. Munoz M, Rosso M, Perez A, et al. the NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 2005;39:427-32
27. Palma C, Nardelli F, Manzini S, et al. Substance P activates responses correlated with tumour growth in human glioma cells line bearing tachykinin NK1 receptors. Br J Cancer 1999;79:236-43
28. Munoz M, Rosso M, Aguilar FJ, et al. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Investig New Drugs 2008;26:111-18
29. Luo W, Sharif TR, Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 1996;56:4983-91
30. Ernst A, Suhr J, Kohrle J, et al. Detection of stable N-terminal protachykinin A immunoreactivity in human plasma and cerebrospinal fluid. Peptides 2008;29:1201-6
31. Rameshwar P, Joshi DD, Yadav P, et al. Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fibrosis. Blood 2001;97:3025-31
32. Entschladen F, Lang K, Drell TL, et al. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother 2002;51:467-82
33. Meshki J, Douglas SD, Lai JP, et al. Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism. J Biol Chem 2009;284:9280-9
34. Fackler OT, Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol 2008;181:879-84
35. Friess H, Zhu Z, Liard V, et al. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 2003;83:731-42
36. Giardina GAM, Gagliardi S, Martinelli M. Antagonists at the neurokinin receptors-Recent patent literature. Drugs 2003;6:758-72
37. Quartara L, Maggi CA. the tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides 1997;31:537-63
38. Quartara L, Altamura M. Tachykinin receptors antagonists: From research to clinic. Curr Drug Targets 2006;7:975-92
39. Varty GB, Cohen-Williams ME, Hunter JC. the antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 2003;14:87-95
40. Rupniak NM, Carlson EC, Harrison T, et al. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 2000;39:1413-21
41. Bang R, Sass G, Kiemer AK, et al. Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J Pharmacol Exp Ther 2003;305:31-9
42. Humphrey JM. Medicinal chemistry of selective neurokinin-1 antagonists. Curr Top Med Chem 2003;3:1423-35
43. Munoz M, Berbabeu Wittel J, Covenas R. NK-1 as a melanoma target. Expert Opin Ther Targets 2011;15:889-97
44. Navari RM. Fosaprepitant (MK-0517): A neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investing Drug 2007;16:1977-85
45. Munoz M, Rosso M. the NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 2010;28:187-93
46. Cahill CM, Coderre TJ. Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist. Pain 2002;95:277-85
47. Huang S-C, Korlipara VL. Neurokinin1 receptor antagonists: A comprehensive patent survey. Expert Opin Ther Patents 2010;20:1019-45
48. Pagan B, Isidro AA, Coppola D, et al. Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer. Anticancer Res 2010;30:3345-53
49. Wang Y, Mu X, Liu Y, et al. NK-1-receptor-mediated lesion of spinal post-synaptic dorsal column neurons might improve intractable visceral pain of cancer origin. Med Hypotheses 2011;76:102-4
50. Rost K, Fleischer F, Nieber K. Neurokinin-1 receptor antagonists: between hope and disappointment. Med Monatsschr Pharm 2006;29:200-5
51. Hargreaves R, Ferreira JC, Hughes D, et al. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann NY Acad Sci 2011;1222:40-8
52. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60:533-6
53. Stander S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: A novel antipruritic strategy. PLoS One 2010;5:e10968
54. Akazawa T, Kwatra SG, Goldsmith LE, et al. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 2009;109:1079-86
55. Huang WQ, Wang JG, Chen L, et al. SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D. J Exp Clin Cancer Res 2010;24:29-55
56. DeFea KA, Vaughn ZD, OBryan EM, et al. the proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 2000;97:11086-91
57. Esteban F, Munoz M, Gonzalez-Moles MA, et al. A role for substance P in cancer promotion and progression: A mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metast Rev 2006;25:137-45
58. Guha S, Eibl G, Kisfalvi K, et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,DTrp5,7,9, Leu11]SP: A dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 2005;65:2738-45
59. Exadaktylos AK, Buggy DJ, Moriarty DC, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006;105:660-4
60. Munoz M, Rosso M, Casinello F, et al. Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Res Treat 2010;122:601-3
61. Kitchens CA, McDonald PR, Pollack IF, et al. Synergy between microtubule destabilizing agents and neurokinin 1 receptor antagonists identified by an siRNA synthetic lethal screen. FASEB J 2009;23:756-13
62. Alfieri AB, Cubeddu LX. Role of NK1 receptors on cisplatin-induced nephrotoxicity in the rat. Naunyn. Schmiebergs. Arch Pharmacol 2000;361:334-8
63. Alfieri AB, Cubeddu LX. Efectos de los antagonistas de los receptores NK1 y de la dexametasona sobre la inflamacion neurogenica inducida por ciclofosfamida y por radiacion X, en la rata. AVFT 2004;23:61-6
64. Sendo T, Itoh Y, Goromaru T, et al. Role of substance P in hypersensitivity reactions induced by paclitaxel, an anticancer agent. Peptides 2004;25:1205-8
65. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136-42
66. Moskowitz MA. the neurobiology of vascular head pain. Ann Neurol 1984;16:157-68
67. Yu J, Cadet JL, Angulo JA. Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J Neurochem 2002;83:613-22
68. Pfizer, Inc. NK-1 receptor antagonists for the treatment of cancer. US5990125; 1999
69. Biopolis S.p.A. Use of substance P antagonists in the treatment of the adenocarcinomas. US6576638; 2003
70. Munoz M. Use of non-peptide NK-1 receptor antagonists for the production of apoptosis in tumor cells. US20090012086; 2004
71. Ensayo clinico. Fase II, de uso de Aprepitant (antagonista de los receptores NK-1) en el tratamiento de pacientes con cancer, No Eudra. CT200500158513; 2005
72. Zhejiang University of Technology. Neurokinin receptor antagonists for preparing anticancer drugs. CN102139107; 2011
73. Cadus Pharmaceutical Corp. Synthesis and use of thiophene and pyrrole-based heteroaromatic compounds. US6037340; 2000
74. Manuel Vicente Salinas Martin. Use of antibodies against NK-1, NK-2 and/or NK-3 receptors in cancer treatment. WO2012020162; 2012
75. Universidad de Barcelona. Use of monoclonal antibodies against substance P to treat cancer. ES200801071; 2008
76. Rameshwar P. Implication of possible therapies targeted for the tachykinergic system with the biology of neurokinin receptors and emerging related proteins. Recent Pat CNS Drug Discov 2007;2:79-84
77. Rameshwar P. Hematopoietic Growth Factor Inducible Neurokinin-1 Gene. US6939955; 2005